Genelux vs Lyell Immunopharma
Lyell Immunopharma is the larger business, with $36,000 of revenue in fiscal 2025 against $8,000 for Genelux (4.5 times as much). Genelux grew faster (0.0% against -41.0%). Genelux kept more of each dollar of sales as profit: a net margin of -401812.5% against -762355.6%. Genelux carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | GeneluxGNLX, 2025 | Lyell ImmunopharmaLYEL, 2025 |
|---|---|---|
| Revenue | $8,000 | $36,000 |
| Revenue growth | 0.0% | -41.0% |
| Net income | −$32.1m | −$274m |
| Operating margin | -415175.0% | -748344.4% |
| Net margin | -401812.5% | -762355.6% |
| Return on equity | -170.0% | -87.0% |
| Free cash flow | −$26.4m | −$151m |
| Cash | $5.3m | $60.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 25 | 161 |
| Market value | $87.5m | $252m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 25 sales | 2 buys, 29 sales |